Biotest AG: Biotest is developing with Trimodulin a COVID-19 therapy for patients with a severe course of the disease
DGAP-News: Biotest AG
/ Key word(s): Research Update
Biotest is developing with Trimodulin a COVID-19 therapy for patients with a severe course of the disease
- Highly innovative plasma protein product with great therapeutic potential
- Existing study shows: Trimodulin can significantly reduce mortality in mechanically ventilated patients with severe pneumonia
- Mode of action transferable to patients with Covid-19 induced pneumonia
- With additional funding, patients could benefit in current pandemic
- Biotest has already invested a three-digit million amount in drug development and a new production plant
Very good results have already been achieved in a large-scale Phase II study in mechanically ventilated patients with severe pneumonia (severe Community Acquired Pneumonia = sCAP) (CIGMA study). This group of diseases also includes pneumonia caused by the current coronavirus in critically ill patients.
Trimodulin is administered as a adjunct to standard therapy such as antiviral or antibiotic therapy, and intensive care. In the CIGMA study, a relative reduction in mortality of 50-70% was observed in a subgroup of patients with high inflammation markers and/or reduced immune function (low immunoglobulin M levels).
The same conditions also occur in Covid-19 patients with severe course of the disease. According to previous studies, the mode of action of Trimodulin includes not only the ability to support the immunological control of pathogens, but also the ability to dampen an excessive malfunction of the immune system and an excessive inflammation reaction.
Due to the great similarity of the clinical picture to the patients treated in the CIGMA study, Biotest sees Trimodulin as having considerable potential for patients with severe pneumonia after Covid-19 infection. Another IgM- and IgA-enriched immunoglobulin of Biotest AG, Pentaglobin(R), has already shown positive results treating f coronavirus infections (SARS 2002/03). No data are yet available on the treatment of Covid-19 with Pentaglobin(R).
That is why Biotest is now expanding its planned Phase III study in sCAP to include Covid-19 patients. At the same time, an accelerated phase II study in Covid-19 patients is planned in order to drastically accelerate the development in response to the current Covid-19 pandemic. Biotest has already applied for European funding for the activities necessary to speed up the development. With Trimodulin, Biotest is developing a promising therapeutic option that could help saving numerous lives.
Biotest has already invested a three-digit million Euro amount in the development of Trimodulin and the associated new production facility. The funding programs for such advanced clinically innovative approaches for the therapy of Covid-19 are unfortunately still small and very limited. In this context, Biotest is hoping for more public support to accelerate drug development in this critical phase of the COVID-19 pandemic.
About Severe Community-Acquired Pneumonia (sCAP)
About Trimodulin (IgM Concentrate)
Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
03.04.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
|Phone:||0 61 03 - 8 01-0|
|Fax:||0 61 03 - 8 01-150|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1015013|
|End of News||DGAP News Service|